| Ytd | -4.76% | |
| 1y | -59.68% |
| Open | 1.02 | Prev Close | 1.02 | Low | 1.00 | High | 1.05 | Mkt Cap | 11.62M |
| Vol | 146.58K | Avg Vol | 158.05K | EPS | -1.38 | P/E | N/A | Forward P/E | 0.07 |
| Beta | 1.47 | Short Ratio | 0.50 | Inst. Own | 3.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.10 | 200-d Avg | 1.35 | 1yr Est | 36.00 |
PHIO News
Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ
Phio entered into a comprehensive drug substance services agreement with Nitto Denko Avecia, Inc. in
Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst co
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop
Recent Company Highlights Phio's lead clinical candidate, PH-762, is being evaluated as an intra
The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating D
Phio Pharma stock fell after a recent rally, despite strong Phase 1b trial results showing an 85% re
HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy an
Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop
Nonclinical protocol study design accepted by FDAStudy to commence in First Quarter 2026King of Prus
Shares of Rumble Inc.
Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a let
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company